(UroToday.com) As a part of the kindey cancer oral abstract session, Dr. Toni Choueiri presented preliminary results from a phase 2 study of belzutifan (MK-6482) in combination with United States Federal Drug Administration (FDA)-approved multiple TKI, cabozantinib. As covered in other presentations throughout this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), greater than 90% of people with clear cell renal cell carcinoma (ccRCC) harbor sporadic genomic alterations resulting in defective VHL protein and a pseudohypoxic state. This latter point is the basis of the rationale for targeting HIF2alpha with belzutifan.